Samsung BioLogics lands $1.3 billion U.S. contract amid tariff uncertainty

1. $1.3 billion contract through 2029 makes this one of Samsung BioLogics’ largest agreements.
2. Expansion plans to nearly 1 million liters of capacity highlight surging global CDMO demand.

Samsung BioLogics has signed a contract worth about 1.8 trillion won, equal to 1.3 billion U.S. dollars, with an American pharmaceutical partner under terms extending through 2029. The South Korean manufacturer already operates 784,000 liters of biologics capacity, the largest in the world. Expansion plans call for nearly one million liters by 2027, reinforcing its global dominance. Analysts believe the undisclosed partner is a top ten U.S. firm, highlighting how companies are securing long-term manufacturing access to guard against trade disruptions. The global contract development and manufacturing sector has been expanding at double-digit annual rates as biologics and cell therapies drive demand. For physicians, the downstream effect is greater stability in supply for advanced treatments, from monoclonal antibodies to immunotherapies. The deal reflects how capacity security is now a strategic priority equal to drug innovation. It also underscores the role of South Korea as a hub in the global pharmaceutical supply chain. While clinicians may not feel these moves directly, the reliability of drug supply ultimately shapes access and patient outcomes. Tariff concerns have only accelerated the urgency to secure cross-border agreements. For Samsung, this represents both growth and a hedge against geopolitical uncertainty that could ripple through the industry.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.